Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

The objective of this study was to evaluate structural damage progression based on clinical response in rheumatoid arthritis patients with no or limited prior disease-modifying anti-rheumatic drug treatment receiving the Janus kinase (JAK)1/JAK2 inhibitor baricitinib 4 mg, methotrexate (MTX), or the...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Rheumatol
Main Authors: van der Heijde, Désirée, Durez, Patrick, Schett, Georg, Naredo, Esperanza, Østergaard, Mikkel, Meszaros, Gabriella, De Leonardis, Francesco, de la Torre, Inmaculada, López-Romero, Pedro, Schlichting, Douglas, Nantz, Eric, Fleischmann, Roy
Formato: Artigo
Idioma:Inglês
Publicado: Springer London 2018
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6097080/
https://ncbi.nlm.nih.gov/pubmed/30078086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10067-018-4221-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares